LBA55 START-001: Initial phase II clinical activity of invikafusp alfa, a first-in-class T cell receptor (TCR) β-chain-targeted bispecific antibody as monotherapy in patients with antigen-rich solid tumors resistant to immune checkpoint blockade (ICB)

E. Garralda; A. Italiano; A. Marabelle; C. Friedman; R.J. Sullivan; K. He; N. Tschernia; A. Hernando Calvo; M. Roulleaux Dugage; M. Pedregal Trujillo; M.M. Herrera Juarez; G.P. Sonpavde; M. Bilusic; A.W. Silk; M. Pelster; C.A. Gomez-Roca; Z. Su; K. Liu; L.L. Siu; J. Gulley

doi:10.1016/j.annonc.2025.09.067

Back

LBA55 START-001: Initial phase II clinical activity of invikafusp alfa, a first-in-class T cell receptor (TCR) β-chain-targeted bispecific antibody as monotherapy in patients with antigen-rich solid tumors resistant to immune checkpoint blockade (ICB)

Journal article

Peer reviewed

LBA55 START-001: Initial phase II clinical activity of invikafusp alfa, a first-in-class T cell receptor (TCR) β-chain-targeted bispecific antibody as monotherapy in patients with antigen-rich solid tumors resistant to immune checkpoint blockade (ICB)

E. Garralda, A. Italiano, A. Marabelle, C. Friedman, R.J. Sullivan, K. He, N. Tschernia, A. Hernando Calvo, M. Roulleaux Dugage, M. Pedregal Trujillo, …

Annals of oncology, Vol.36, pp.S1714-S1714

2025-09

DOI: https://doi.org/10.1016/j.annonc.2025.09.067

Appears in Miller School of Medicine - Latest Publications

Metrics

1 Record Views

Details

Title: LBA55 START-001: Initial phase II clinical activity of invikafusp alfa, a first-in-class T cell receptor (TCR) β-chain-targeted bispecific antibody as monotherapy in patients with antigen-rich solid tumors resistant to immune checkpoint blockade (ICB)
Creators: E. Garralda - Vall d'Hebron Institute of Oncology
A. Italiano - Department of Medicine, Institute Bergonié, Bordeaux, France
A. Marabelle - Institut Gustave Roussy
C. Friedman - Memorial Sloan Kettering Cancer Center
R.J. Sullivan - Massachusetts General Hospital
K. He - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
N. Tschernia - Center for Immuno-Oncology, National Cancer Institute, NIH, Bethesda, United States of America
A. Hernando Calvo - Vall d'Hebron Institute of Oncology
M. Roulleaux Dugage - Institut Gustave Roussy
M. Pedregal Trujillo - Start
M.M. Herrera Juarez - Medical Oncology and Hematology Department, Princess Margaret Cancer Centre, Toronto, Canada
G.P. Sonpavde - Division of Hematology/Oncology, AdventHealth Central Florida, Orlando, United States of America
M. Bilusic - Genitourinary Medical Oncology, UH Health - University of Miami Health System - Miller School of Medicine, Coral Gables, United States of America
A.W. Silk - Dana-Farber Cancer Institute
M. Pelster - Sarah Cannon Research Institute
C.A. Gomez-Roca - Institut universitaire du cancer de Toulouse Oncopole
Z. Su - Oncology, Marengo Therapeutics, Inc., Cambridge, United States of America
K. Liu - Oncology, Marengo Therapeutics, Inc., Cambridge, United States of America
L.L. Siu - Princess Margaret Cancer Centre
J. Gulley - Center for Immuno-Oncology, National Cancer Institute, NIH, Bethesda, United States of America
Publication Details: Annals of oncology, Vol.36, pp.S1714-S1714
Publisher: Elsevier Ltd
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991032900559402976